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Abstract
Glioblastoma (GBM) is the most frequent malignant glioma. Treatment of GBM patients is multimodal with max-
imum surgical resection, followed by concurrent radiation and chemotherapy with the alkylating drug temozolo-
mide (TMZ). The present study aims to identify genes implicated in the acquired resistance of two human GBM
cells of astrocytic origin, T98G and U373, to TMZ. Resistance to TMZ was induced by culturing these cells in vitro
for months with incremental TMZ concentrations up to 1 mM. Only partial resistance to TMZ has been achieved
and was demonstrated in vivo in immunocompromised mice bearing orthotopic U373 and T98G xenografts. Our
data show that long-term treatment of human astroglioma cells with TMZ induces increased expression of facil-
itative glucose transporter/solute carrier GLUT/SLC2A family members, mainly GLUT-3, and of the AKR1C family of
proteins. The latter proteins are phase 1 drug-metabolizing enzymes involved in the maintenance of steroid homeo-
stasis, prostaglandin metabolism, and metabolic activation of polycyclic aromatic hydrocarbons. GLUT-3 has been
previously suggested to exert roles in GBM neovascularization processes, and TMZ was found to exert antiangio-
genic effects in experimental gliomas. AKR1C1 was previously shown to be associated with oncogenic potential,
with proproliferative effects similar to AKR1C3 in the latter case. Both AKR1C1 and AKR1C2 proteins are involved
in cancer pro-proliferative cell chemoresistance. Selective targeting of GLUT-3 in GBM and/or AKR1C proteins (by
means of jasmonates, for example) could thus delay the acquisition of resistance to TMZ of astroglioma cells in the
context of prolonged treatment with this drug.
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Introduction
Malignant gliomas represent the most common type of primary brain
tumor and constitute a spectrum of clinicopathologic entities from
low- to high-grade malignancies. Nearly all low-grade tumors (except
grade 1) eventually progress to high-grademalignancies [1]. Glioblastoma
(GBM) is the most frequent and malignant glioma [2]. Treatment of
GBM patients is multimodal with maximum surgical resection, fol-
lowed by concurrent radiation and chemotherapy with the alkylating
drug temozolomide (TMZ) and/or with nitrosourea [3–7]. However,
whereas these treatments prolong GBM patient survival, they do not
affect the overall dismal prognosis of this disease. No GBM patient
has been cured to date [3–7] because of the diffuse nature of GBM cell
invasion into the brain parenchyma and the natural resistance of GBM-
migrating cells to apoptosis and thus to chemotherapy and radiotherapy
[6]. One of the most beneficial treatments for GBM patients is surgery
followed by radiotherapy with concomitant TMZ administration [3–5].
Moreover, TMZ increases GBM sensitivity to radiotherapy [3–5] most
effectively in O6-methylguanine-DNA methyltransferase–negative
GBMs by increasing the degree of radiation-induced double-strand
DNA damage [8]. TMZ can also prevent irradiation-induced glioma
cell invasion [9] through caspase-mediated prevention of irradiation-
induced FAK activation [10]. TMZ also displays antiangiogenic effects
in experimental gliomas [11]. TMZ has been shown to first induce
proautophagic defenses in GBM cells [12,13], a feature that leads to
late apoptosis [14]. Thus, although TMZ does not cure GBM patients,
it significantly improves GBM patient survival and quality of life. Stupp
et al. [5] assigned 573 GBM patients to treatment; 278 (97%) of the
286 patients in the radiotherapy-alone group and 254 (89%) of 287
in the combined treatment radiotherapy and TMZ group died during
the 5 years of follow-up. Overall survival rates were 27% at 2 years, 16%
at 3 years, 12% at 4 years, and 10% at 5 years with TMZ versus 11%,
4%, 3%, and 2% with radiotherapy alone, respectively [5]. A benefit of
combined therapy was recorded in all clinical prognostic subgroups, in-
cluding patients aged 60 to 70 years [5].
However, GBMs can present innate resistance to TMZ or develop
acquired resistance during treatment [4,6]. Innate resistance of GBM
cells to TMZ includes various events, such as loss of the phosphatase
and tensin homolog, leading to the activation of the phosphoinositide-
3-kinase/Akt pathway [6,15], unmethylation of O6-methylguanine-
DNA methyltransferase [16], robust base excision repair [17], high
activity of the DNA repair protein O6-alkylguanine-DNA alkyl-
transferase [18], and deficiency in the DNA mismatch repair system
[19]. Acquired resistance of GBM cells to TMZ during treatment
includes loss of the mismatch repair protein MSH6 [20] and the se-
lection of less-differentiated preexisting resistant cells in the parental
tumor [21].
The present study aimed to identify genes implicated in acquired
resistance of two human GBM cells of astrocytic origin, T98G and
U373 [22,23]. Resistance to TMZwas induced in these cells by cultur-
ing them in vitro overmonthswith incremental TMZconcentrations up
to 1mM.Only partial resistance to TMZ has been achieved in vivo, and
this demonstrated in immunocompromised mice bearing orthotopic
U373 andT98G xenografts.Whole-genome analyses (Affymetrix,High
Wycombe, UK), along with proteomic validations (Western blot anal-
ysis and immunofluorescence), were performed in the U373 and T98G
GBMcells that were treated for months with TMZ and in the untreated
control cells. Stem cell markers were also analyzed in the various GBM
cell variants because GBM response to TMZ can be influenced by the
proportion and/or nature of GBM stem cells [24–28].
Materials and Methods
Cell Lines, Media, and Compounds
Established cell lines. The human U373 (ATCC code HTB-17)
GBM, T98G (ATCC code CRL1690) GBM, and the human HT29
colon cancer (ATCC code HTB-38) cell lines were obtained from the
American Type Culture Collection (ATCC, Manassas, VA) and main-
tained in our laboratory as detailed previously [21,22].
Compounds. TMZ was obtained from Schering Plough (Brussels,
Belgium).
Long-term Treatment of U373 and T98G GBM Cell
Lines with TMZ
U373 and T98GGBMcell lines were treated as follows: (a) 0.1 μM
TMZ two times per week (Monday and Thursday) for 4 weeks (with
fresh medium change at each TMZ treatment), (b) 1 μM TMZ two
times per week for 5 weeks, (c) 10 μM TMZ two times per week for
12 weeks with 1 week of washout after each week of TMZ treatment,
(d ) 500 μM TMZ once a week for 3 weeks with 1 week of washout
between the 2 weeks of TMZ treatment, (e) 500 μMTMZ two times
per week for 8 weeks with 1 week of washout between 2weeks of TMZ
treatment, and ( f ) 1 mM TMZ two times per week for 4 weeks with
1 week of washout between the weeks of TMZ treatment. The cells
were analyzed for genomic and proteomic purposes after 4 weeks of
washout after the treatment described in ( f ). U373 andT98GBMcells
remained permanently cultured in the presence of 150μMTMZ for the
experiments performed in the current study.
Animal Models
In vivo orthotopic xenografts of human U373 and T98G cells left
untreated and thus sensitive (“TMZ-S” phenotype) versus TMZ long-
term treated (“TMZ-LTT” phenotype) GBM cells were obtained as
described previously [21,22]. All mice (6-week-old female nu/numice
of 21-23 g; Janvier, Le Genest-Saint-Isle, France) had GBM TMZ-S
(11 mice per group/experimental model) or TMZ-LTT (11 mice per
group/experimental model) cells stereotactically implanted into their
brains on the same day. All of the in vivo experiments described in the
present study were performed based on authorization no. LA1230509
of the Animal Ethics Committee of the Federal Department of Health,
Nutritional Safety and the Environment (Belgium).
Analyses of GLUT Transporter and AKR1C Enzyme Genomic
Expression in a Clinical Series of 159 Gliomas and 23 Normal
Brain Samples from the Henry Ford Hospital
The genomic expression of four GLUT transporters (GLUT-1, -3,
-5, and -10) and three AKR1C enzymes (AKR1C1, AKR1C2, and
AKR1C3) was analyzed in a series of 179 human brain samples that
included 23 normal brain tissues, 10 grade 2 astrocytomas, 19 grade 3
astrocytomas, 77 GBMs, 38 grade 2 oligodendrogliomas, and 12 grade 3
oligodendrogliomas. Microarray data were generated by the Henry Ford
Hospital (Detroit, MI) from the Affymetrix Array Series GSE4290, and
these are available at: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE4290.
Reverse Transcription–Polymerase Chain Reaction Analyses
Total RNA was extracted using the TRIzol isolation reagent (Life
Technologies, Inc, Merelbeke, Belgium) according to the manufac-
turer’s instructions. The extracted RNAwas treated with DNase I (Life
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Technologies, Inc) to eliminate any remaining genomic DNA. The
quality and integrity of the extracted RNA were assessed using both the
BioAnalyzer 2100 (Agilent, Toulouse, France) and gel electrophoresis.
Reverse transcription (RT) reactions were carried out in a thermal
cycler (Thermocycler; Westburg, Leusden, the Netherlands). The
purification of the complementary DNA (cDNA) produced was per-
formed using the High Pure PCR Product Purification Kit (Roche
Diagnostics, Mannheim, Germany) in accordance with the manufac-
turer’s instructions. The integrity of the cDNA was confirmed by an
analysis of β-actin gene expression on the basis of a 25-cycle standard
polymerase chain reaction (PCR) analysis in a total volume of 50 μl
with 20 ng of cDNA. Standard PCRs were carried out in a thermal
cycler (Thermocycler; Westburg). The thermal profiles were as follows:
predenaturation for 4 minutes at 95°C, denaturation for 45 seconds at
95°C, annealing for 45 seconds at their respective hybridizing tempera-
tures (Tm), elongation for 1 minute and 15 seconds at 72°C, and a
final elongation for 10 minutes at 72°C. The PCR products were ob-
tained after 35 thermal cycles. All of the PCR analyses were performed
based on the same quantity of purified cDNA (total amount, 20 ng).
The products that were amplified by means of the standard PCR were
resolved by gel electrophoresis in 1.2% agarose TAE gels in parallel
with a 1-kb plus DNA ladder (Invitrogen, Merelbeke, Belgium) and
visualized with SYBR safe (Invitrogen) staining under UV light. The
following primers and their Tm values were used: Nestin: forward 5′-
ggatcagatgacattaagacc-3′ and reverse 5′-ccgtatcttcccacctct-3′ (Tm = 59°C);
glial fibrillary acidic protein (GFAP): forward 5′-gttctctcggagtatctgg-3′
and reverse 5′ccctacttgtatgcctagtg-3′ (Tm = 59°C); CD90: forward 5′-
cctaaggaagctaaaagcatg-3′ and reverse 5′-ctcaatgagatgccataagct-3′ (Tm =
57°C); vimentin: forward 5′-gattcaggaacagcatgtc-3′ and reverse 5′-
tctctagtttcaaccgtctta-3′ (Tm = 57°C); CK20: forward 5′-gaacctaaa-
tgaccgtctagc-3′ and reverse 5′-ccaaatctgttttatgtaagggttag-3′ (Tm =
59°C); CD44: forward 5′-ggcttagacagagttgatct-3′ and reverse 5′-
ggctatgagacttgtatcactac-3′ (Tm = 57°C); CD133: forward 5′-gagagtaac-
taggattctagctt-3′ and reverse 5′-ccattcgacgatagtacttagc-3′ (Tm = 57°C);
maternal embryonic leucine zipper kinase (MELK): forward 5′-gtgaa-
tccagatcaactgttg-3′ and reverse 5′-gctagataggatgtcttccacta-3′ (Tm =
57°C); and actin: forward 5′-ctaagtcatagtccgcctag-3′ and reverse
5′-aaatcgtgcgtgacattaagg-3′ (Tm = 62°C).
Genomic Analyses
Whole genomic analyses were performed on U373 and T98G
TMZ-S versus TMZ-LTT GBM cells at the VIB MicroArray Facility
(UZ Gasthuisberg, Catholic University of Leuven, Leuven, Belgium)
using the Affymetrix Human Genome U133 set Plus 2.0. We are ex-
pressing the genomic-related data as medians and median absolute
deviations (MADs). Data analysis was carried out as described previ-
ously [29,30].
Proteomic Analyses
Western blot analysis. Proteins were electrophoresed on a 10%
SDS-PAGE using a Bio-Rad electrophoresis unit at 100 V for 1 hour
and transferred onto nitrocellulose membranes. The membranes were
blocked in Tris-buffered saline containing 0.1%Tween-20 and 5% fat-
free milk or 5% bovine serum albumin for 1 hour. Membranes were
incubated overnight with primary antibodies at different concentrations:
monoclonal mouse anti-AKR1C3 (1:500; Sigma, Bornem, Belgium),
polyclonal rabbit anti-AKR1C2 (1:500; Abnova, Taipei, Taiwan), poly-
clonal rabbit anti-Glut10 (1:500; Abcam, Cambridge, UK), and poly-
clonal rabbit anti-Glut3 (1:150; Abcam). Proteins expression was
detected by incubating the membrane with the appropriate secondary
antibodies. Immunoreactive protein bands were detected using the
Pierce Supersignal Chemiluminescence system (Thermo Fisher Scien-
tific, Erembodegem, Belgium).
Immunofluorescence analyses. Cells were cultured on coverslips
and fixed with 4% formaldehyde in PBS for 20 minutes at 4°C. Fixed
cells were permeabilized by adding 0.2% (vol./vol.) Triton X-100 and
10% (wt./vol.) bovine serum albumin for a total of 20 minutes. Cells
were washed twice with PBS and blocked in PBS containing 0.1% of
bovine serum albumin for 1 hour at room temperature. Cells were then
stained for 1 hour at room temperature with a polyclonal antibody
against GLUT-10 and GLUT-3 (Abcam). Antigens were detected us-
ing antirabbit secondary antibodies conjugated to Alexa Fluor 488 (In-
vitrogen). Coverslips were mounted onmicroscope slides with 10 μl of
Moviol agent (Calbiochem, VWR, Heverlee, Belgium). Pictures were
obtained using a 40× microscope oil immersion objective (Zeiss ob-
server.Z1; Zeiss, Oberkochen, Germany) and an Axiocam HRm Zeiss
camera controlled by software. Pictures were converted to stacks and
navigated using the Axiovision Rel 4.6 software. Three coverslips were
analyzed, and three pictures were taken for each coverslip (with the
same exposure time) for each condition (TMZ-S vs TMZ-LTT cell
lines). The most representative data are shown.
Transient Knock-down of AKR1C Expression by Means of an
Anti-AKR1C Small Interfering RNA in Human T98G and
U373 GBM Cells
We have tested three different sequences of anti-AKR1C3 small in-
terfering rNA (siRNA), and we have chosen the most efficient one for
carrying out the silencing process. The sequence of this anti-AKR1C3
siRNA (Eurogentec, Seraing, Belgium) is 5′-GGUGAGGAACUUU-
CACCAA-3′ for the sense sequence and 5′-UUGGUGAAAGUUC-
CUCACC-3′ for the antisense sequence. A siRNA-negative control
(scramble; Eurogentec) was used as a process control. The sense and
the antisense strands were annealed by the manufacturer in 50 mM
Tris, pH 7.5 to 8.0, in 100 nM diethylpyrocarbonate-treated water.
The final concentration of the siRNA duplex was 100 μM.
U373 and T98G TMZ-LTT and TMZ-S cells lines were trans-
fected with DiC14-amidine/siRNA lipoplexes. DiC14-amidine (3-
tetradecylamino-N -tert-butyl-N -tetradecylpropionamidine) was
synthesized as previously described [31], and liposomes were prepared
as previously [32]. Briefly, after having dissolved DiC14-amidine in
chloroform, the solvent was evaporated under a steam of N2. The
resulting lipid film was further dried under vacuum overnight then
hydrated with prewarmed buffer (10 nM HEPES, 150 mM NaCl at
pH 7.3) to reach a concentration of 10 mM and vortexed for 1 minute.
Liposomes were then extruded seven times through a 0.4-μm polycar-
bonate filter (GE Osmonics, Herentals, Belgium) at 55°C and stored at
4°C in a 4-ml polystyrene tube (Falcon, VWR, Heverlee, Belgium). For
experiments, liposomes were heated for 2 hours at 55°C before use.
To form the DiC14-amidine/siRNA lipoplexes, a volume of siRNA
at 0.4 μM (usually 200 μl) was added into an equal volume of lipo-
somes (20 μg of diC14-amidine/ml) in RPMI (Invitrogen) while gently
shaking the tube. The liposome/siRNA mixture was allowed to stand
for 20minutes at room temperature before use. Under these conditions,
the lipoplex has a cationic lipid/siRNA ratio of 7.5:1 (wt./wt.), and the
charge ratio is calculated to be 4.54 positive charges for 1 negative charge.
The liposome/siRNA mixture (at a final concentration of 0.032 μM
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in siRNA) was added to U373 and T98GTMZ-LTTand TMZ-S cells
for 2 hours. On day 2, each group of cells was pooled and replated for
subsequent experiments. On days 3, 5, 7, and 9, glioma cells were lysed
directly in Cellytic solution (Sigma). The efficiency of the AKR1C3
siRNA was evaluated by means of Western blot analysis.
Computer-Assisted Phase-Contrast Video Microscopy
For human U373 and T98G GBM cell lines, the effects of long-
term treatment with TMZ and AKR1C3 siRNA (vs scramble siRNA)
on cell viability, growth, and division were characterized in vitro by the
use of computer-assisted phase-contrast videomicroscopy, as described
elsewhere [33]. Cells were monitored for 72 hours. Films were com-
piled on the obtained time-lapse image sequences, which enabled a
rapid screening of cell viability.
Cell count–based determination of global growth ratio. In each
(control or treated) condition, the cell growth level was evaluated by
the ratio between the numbers of cells counted in the last and first
frames of the image sequences. The global growth ratio (GGR) was
defined by the ratio between the two growth levels obtained in the
treated and control conditions. All of the cell counts were performed in
triplicate using an interactive computer tool [33,34]. The GGRs were
computed at the 24th, the 48th and the 72nd hour of quantitative video
microscopy analyses by dividing the cell growth level in TMZ-LTT
GBM cell populations by the cell growth level at the same experimental
times in the corresponding TMZ-S GBM cell populations. In the
AKR1C3 siRNA experiments, we followed the number of cells for
6 days (2 days after transfection). For a quantitative measure of pro-
liferation on AKR1C3 siRNA, the GGRs were computed between
siRNA and scramble conditions at 3, 5, 7, and 9 days after transfection.
Specific analysis of cell division rate and duration. Cells under-
going division exhibit very bright patterns compared with nondividing
cells. On the basis of this observation, we developed a custom division
detection system capable of identifying cells undergoing division in
time-lapse sequences. This detection method is based on an automatic
event detection completed by an interactive validation/correction pro-
cedure as previously described [33,34]. At the end of the sequence
analysis, all events are linked to different cell divisions, making avail-
able the number of cell divisions as well as their durations [33,34]. We
computed the cell division numbers normalized by the number of cells
that were counted in the first frame.
Determination of In Vitro Cell Cycle Kinetics
TMZ-S and TMZ-LTT GBM cells were incubated for 72 hours in
culture medium. Cells were collected by trypsinization and were neu-
tralizedwith cellmedium.Cell suspensionswere centrifuged for 10min-
utes at 1000 rpm at room temperature and then washed two times
with PBS before being fixed in 70% ethanol. Cells were stored at
−20°C for 24 hours. Flow cytometry using propidium iodide was
performed. Briefly, fixed samples were washed with PBS and resus-
pended in propidium iodide (1 mg/ml) and RNase (200 μg/ml) for
at least 30 minutes at 37°C in the dark. Stained cells were analyzed
on a cell laboratory Quanta SC flow cytometer (Beckman Coulter,
Suarlée, Belgium).
We analyzed the percentage of cells in theG0/G1, S, andG2/Mphases
of the cell cycle and took into account the percentage of polyploid cells
(as detailed elsewhere [35,36]) that were removed from the cell cycle
kinetic determination.
Statistical Analyses
Data obtained from independent groups were compared by the
nonparametric Kruskal-Wallis (more than two groups) or Mann-
Whitney U tests (two groups). The standard survival time analyses
were carried out with the log-rank test. The statistical analysis was per-
formed using Statistica software (Statsoft, Tulsa, OK).
Results
Chronic In Vivo Treatment of TMZ-S and TMZ-LTT U373
and T98G Orthotopic GBM Xenografts with TMZ
Figure 1A shows that without additional TMZ treatment, the U373
TMZ-LTT xenografts in vivo displayed more aggressive behavior
in vivo than U373 TMZ-S xenografts in survival (P < .001). This fea-
ture has not been observed with the T98G model (Figure 1B). The ag-
gressive nature of U373 TMZ-LTT xenografts when compared with
U373 TMZ-S cells seems to be partially associated with the higher
invasive pattern for U373 TMZ-LTT xenografts, as illustrated in
Figure 1C . For all tested models, per os TMZ treatment strongly and
significantly improved mouse survival (Figure 1, A and B). It should be
noted that we killed all mice after 287 days to avoid contamination. To
characterize the resistance acquisition in the TMZ-LTT groups, we
computed survival gains as being the differences of the median survival
times between each treated group and its respective control. For the
U373 TMZ-S group, the median survival was 116 days for the control
and up to 287 days for the treated group, whereas the median survival
was 51 days for the control and 203 days for the TMZ-LTT–treated
group (Figure 1A). The survival gains were 152 days for the TMZ-LTT
group and up to 171 days in the TMZ-S group. We performed similar
studies for the T98G cell lines. The survival gains were 124 days for
the TMZ-LTTand up to 222 days for the TMZ-S groups (Figure 1B).
The diminution in survival gain for the TMZ-LTT group compared
with the TMZ-S group suggests that long-term treatment with TMZ
induces the development of a certain level of resistance to this chemo-
therapeutic agent, whereas full resistance has not been reached.
The TMZ IC50 (inhibitory concentration 50%) in vitro growth-
inhibitory concentrations ranged between 150 and 200 μM for TMZ-S
groups in U373 and T98G cell lines (as revealed by the MTT colori-
metric assay; data not shown), whereas TMZ-LTT U373 and T98G
cells were adapted to grow up to 1 mM.
Characterization of Cancer Stem Cell Profiles in TMZ-LTT
versus TMZ-S U373 and T98G GBM Cells
Beier et al. [28] recently demonstrated that TMZ induces a dose- and
time-dependent decline of the stem cell subpopulation (i.e., CD133+
cells) in various experimental glioma models. We thus analyzed the
expression of CD133 and other stem cell markers such as CD44,
nestin, andMELK [24,37] in TMZ-LTTU373 and T98GGBMcells
and compared the expression to the levels found in TMZ-S cells. The
RT-PCR analyses (Figure 1D) did not reveal any difference in the pat-
terns of expression of stem cell markers in U373 and T98G TMZ-S
versus TMZ-LTTGBMcells [22,23]. Indeed, in our current study, long-
term TMZ treatment did not eliminate CD133+ cells in the U373 and
T98G GBM cell lines (Figure 1D) [22,23], whereas we had previously
shown that this occurred with Hs683 malignant oligodendroglioma cells
[30]. It has been established that highlymalignant gliomas contain various
proportions of astrocytic versus oligodendroglial tumor cells [38,39].
Thus, the possibility remains that TMZ preferentially eliminates
CD133+ cells in malignant gliomas with an oligodendroglial component.
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It must be noted that U373 GBM cells express GFAP depending on
the substratumonwhich the cells are cultured [22]. In the current study,
the GBM cells were cultured on plastic.
The human HT29 colon cancer cells were used as a control cell pop-
ulation to illustrate the absence of vimentin and the presence of cyto-
keratin CK20 expression in these cells (Figure 1D).
Cell Population Growth Dynamics and Cell Cycle Kinetics
Table 1 reveals that genes involved in cell proliferation enabled the
best discrimination between U373 and T98GTMZ-S and TMZ-LTT
cells.We therefore made use of quantitative videomicroscopy and flow
cytometry to analyze the growth dynamics and cell cycle kinetics of the
U373 and T98G TMZ-S versus TMZ-LTT GBM cell populations.
Figure 2A shows that U373 TMZ-LTT GBM cells display higher
growth kinetic rates over time when compared with U373 TMZ-S
GBM cells, as shown by the GGR index. Indeed, a GGR of about
1.4 at 24 hours for U373 LTT cell indicates that the growth level
was 1.4 times higher in the U373 TMZ-LTT GBM cell population
at the 24th hour of the quantitative video microscopy analysis when
compared with the growth rate of U373 TMZ-S cells. This increase in
cell grow rate consistent with the in vivo data illustrated in Figure 1A,
1Ca, and 1Cb clearly shows higher biological aggressiveness for U373
TMZ-LTT GBM cells compared with U373 TMZ-S GBM cells. In
contrast, T98G TMZ-LTT GBM cells seem to grow slower than
T98G TMZ-S cells (Figure 2A). This feature has been validated by
the in vitro experiments reported below and could, at least partly, relate
Figure 1. Survival of immunocompromised mice with brain xenografts of TMZ-S (blue dots) versus TMZ-LTT (red triangles) U373 (A) and
T98G (B) GBM cells. Mice were orthotopically grafted into their brains with 106 U373 or T98G tumor cells on day 0 (D0). U373 and T98G
GBM cells that previously grew in vitro for months in the presence of 1 mM TMZ are labeled “TMZ-LTT,”whereas those without any TMZ
treatment in vitro are labeled “TMZ-S” (see Materials and Methods). The mice bearing orthotopic TMZ-S (blue symbols) versus TMZ-LTT
(red symbols) GBM xenografts (11 mice per experimental group) were left untreated (open symbols) or were treated with TMZ (full
symbols). The TMZ treatment (80 mg/kg per os) was given three times a week (Monday, Wednesday, and Friday) for three consecutive
weeks, with treatment started on D14. For each cell line, the P value was calculated by comparing the control and the treated groups, in
addition to comparing the two CT groups in (A). (C) Morphologic illustrations (hematoxylin-eosin staining, ×40) of a TMZ-S (Ca) versus a
TMZ-LTT (Cb) U373 orthotopic xenograft in the brains of immunocompromised mice after having injected 106 TMZ-S or TMZ-LTT U373
GBMcells 42 days earlier.BP indicates brain parenchyma; T , tumor. Arrows show tumor islets invading the normal parenchyma. (D)mRNA
expression (RT-PCR analysis) of nestin, GFAP, vimentin, cytokeratin 20 (CK20), CD133, CD90, CD44, and MELK in U373 and T98G TMZ-S
and TMZ-LTT cells. HT-29 colon cancer cells were used as an internal control. Actin RT-PCR was used as a quality control for the reverse
transcription and the PCR.
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to acquired dependence to the chemotherapeutic as already demon-
strated by Martello et al. [40].
We performed flow cytometry analysis to investigate the cell cycle
kinetics in U373 and T98G TMZ-LTT versus TMZ-S cell popula-
tions (Figure 2B). No significant differences were found in terms of
cell cycle kinetics between these various GBM cell populations
(Figure 2B). We made use of T98G GBM TMZ-S cells treated for
72 hours with 150 μM TMZ as a positive control (Ct+) for the flow
cytometry analysis.
The data in Figure 2C show that the higher growth kinetics (as
revealed by the GGR assessment in Figure 2A) observed in U373
TMZ-LTT GBM cells when compared with TMZ-S counterparts
(Figure 2A) could be partially attributed to an increased mitotic rate,
with the fraction in G1, S, and G2 phases remaining unaffected between
TMZ-LTT and TMZ-S GBM cells (Figure 2B). Similarly, the lower
growth kinetics observed in T98G TMZ-LTT GBM cells when com-
pared with TMZ-S counterparts (Figure 2A) could be partially attrib-
uted to a weaker mitotic rate (Figure 2C ). The higher mitotic rate
observed in U373 TMZ-LTT GBM cells when compared with the
TMZ-S counterparts (Figure 2C ) seems to translate into shortened
(P < .001) mitosis duration times (data not shown). In a similar fashion,
the decrease in mitotic rates observed in T98G TMZ-LTT GBM cells
when compared with the TMZ-S counterparts (Figure 2C ) seems to
translate to increased (P < .001) mitosis duration times (data not shown).
Whole Human Genome Analyses in GBM TMZ-S versus
GBM TMZ-LTT Models
Table 1 details the gene categories whose expression profiles were
significantly altered in humanU373 and T98GGBMcell lines treated
for long periods with increasing concentrations of TMZ up to 1 mM.
The genes that were most significantly altered both in the U373 and
T98G GBM models included the AKR1C (AKR1C1, AKR1C2, and
AKR1C3) and GLUT transporter (mainlyGLUT-1,GLUT-3,GLUT-5,
and GLUT-10) families of genes. We therefore focused our attention
on the proteomic expressions of these genes in the U373 and T98G
TMZ-S and TMZ-LTT cell lines.
Figure 2D illustrates which were the three genes whose expression
were the most increased during long-term TMZ treatment. For exam-
ple, “SCRG1 ×13” indicates that the expression of the SCRG1 gene
was increased by 13 times under prolonged treatment with TMZ. It
is interesting to note that SCRG1 is a potential marker of autophagy
[41], knowing that TMZ indeed induces marked proautophagic ef-
fects in GBM cells [12,13].
The GLUT genes. Figure 3 shows that GLUT-1 was already highly
expressed in the U373 and T98G TMZ-S cells and that treating these
cells for long periods with increasing concentrations of TMZ only
slightly increased GLUT-1 expression in the U373 and T98G TMZ-
LTT cells. The data obtained from clinical samples confirm the high
levels of GLUT-1 expression in clinical samples of gliomas as well as in
normal brain tissues, with no differences in expression between the
various histopathologic groups.
Sustained treatment of U373 and T98G TMZ-S GBM cells with
TMZ increased GLUT-3 expression in both cell lines. We therefore
decided to investigate GLUT-3 expression at the proteomic level in
these cell lines. Figure 4, A and B, shows that we failed to detect an
increase in GLUT-3 and GLUT-10 expressions using Western blot
analysis. We thus proceeded with immunofluorescence analysis and
Table 1. Gene Categories Underexpressed or Overexpressed in the Set of Genes Detected as Differentially Expressed in Human U373 and T98G GBM Left Untreated (S) versus TMZ Long-term Treated
(LTT) Cells.
System* Gene Category† List Population Ease Score‡ Bootstrap Score§ Genes LTT/S Ratio
Hits¶ Total# Hits** Total††
U373
Biological system Cell proliferation 5 94 1040 10,979 0.00004 0.001 SPP1 11.5
RRM2 4.1
SPOCK1 3.2
Molecular function Trans-1/2-dihydrobenzene-1/2-diol dehydrogenase activity 3 96 3 11,107 0.0002 0.005 AKR1C1 4.2
AKR1C2 3.6
AKR1C3 3.1
Cellular component Extracellular space 5 95 391 10,824 0.0006 0.005 SULF1 8.5
IGFBP5 4.9
IGFBP2 4.1
T98G
Biological system Mitotic cell cycle 5 334 329 10,937 0.0003 0.001 RRM2 0.2
CCNA2 0.2
MCM6 0.3
Biological process Cell cycle 6 334 690 10,937 0.0005 0.001 CCMB1 0.3
SMC4 0.3
PBK 0.3
Biological process Cell proliferation 6 334 1036 10,937 0.0006 0.001 RARRES3 6.3
BST2 5.4
BTC 4.7
*The system of categorizing genes (e.g., “GO (gene ontology) Biological System”) in the databases provided by the EASE software package [29,30].
†The specific category of genes within the system.
‡The probability value characterizing the change of proportion between the two ratios: population hits/population total and list_hits/list_total. It constitutes the upper band of the distribution of leave-1-
out Fisher exact probabilities computed on these two ratios.
§An iteratively running overrepresentation analysis on random gene lists to determine true probability more accurately.
¶The number of genes in the list of differentially expressed genes (list_diff resulting from the microarray data analysis) that belong to the Gene Category.
#The number of genes in list_diff that belong to any gene category within the system.
**The number of genes in the total group of genes assayed (list_tot) that belong to the specific gene category.
††The number of genes in list_tot that belong to any gene category within the system.
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observed variations in the expression of the two glucose transporters,
which may partly explain the apparent discrepancies between the
Western blot and immunofluorescence analyses. The latter show that
GLUT-10 protein expression is indeed more important in U373
TMZ-LTT (Figure 4Cb) than in U373 TMZ-S (Figure 4Ca) GBM
cells. We obtained similar data with T98G TMZ-S versus TMZ-LTT
GBM cells (data not shown). In fact, the expression of GLUT-10 is lo-
calized to a perinuclear body, the nature of which has been already dem-
onstrated by Coucke et al. [42]. Figure 4Cd highlights the GLUT-10
perinuclear localization, with the corresponding bright field in
Figure 4Cc.
We also observed an increase in GLUT-3 perinuclear protein ex-
pression in U373 TMZ-LTT (Figure 4Db) and T98G TMZ-LTT
(data not shown) compared with U373 TMZ-S (Figure 4Da) and
T98G TMZ-S (data not shown) GBM cells.
Sustained TMZ treatment increased GLUT-5 messenger RNA
(mRNA) levels in U373 GBM cells (GLUT-5 seems not to be ex-
pressed in T98G GBM cells) and GLUT-10 mRNA levels in T98G
GBM cells, with significant levels ofGLUT-10mRNA already present
in U373 TMZ-S GBM cells (Figure 3). When analyzing the glioma
clinical samples, GLUT-10 mRNA expression levels were maximal
in GBMs, whereas GLUT-3 and GLUT-5 mRNA levels displayed
heterogeneous patterns among the various histopathologic groups
under study.
The AKR1C genes. Figure 5 shows that sustained treatment of
U373 andT98GGBMcells with TMZ for long periods (several months)
led to marked increases in AKR1C1, AKR1C2, and AKR1C3 mRNA
levels, a feature that has been confirmed at the proteomic level for
AKR1C2 and AKR1C3, as illustrated at the bottom of Figure 5.We also
investigated the patterns of AKR1C1 expression in U373 and T98G
TMZ-S versus TMZ-LTTat the proteomic level but could not confirm
the overexpression of AKR1C1 observed at the mRNA level (data
not shown).
As detailed in the Discussion, AKR1C gene products are implicated
in chemoresistance and cell proliferation processes. Reducing AKR1C3
expression inU373 and T98GGBMcells affected cell behavior on two
levels: 1) the growth dynamics of U373 and T98G GBM cell popula-
tions (by means of quantitative video microscopy) and 2) the sensitivity
of U373 and T98G GBM cells to TMZ (by means of the MTT color-
imetric assay). We focused on AKR1C3 because we were able to design
selective and efficient silencing for AKR1C3. We have not investigated
Figure 2. (A) In vitro global growth rate determination (by means of the GGR assessment as described in Materials and Methods) of
U373 and T98G TMZ-LTT GBM cells compared with the TMZ-S counterparts (see Figure 1 and its legend). (B) Flow cytometry analysis for
cell cycle kinetic determination in U373 versus T98G TMZ-S versus TMZ-LTT cells. Sub-G1 cells were excluded from the cell cycle kinetic
analysis using a methodology that was detailed previously [39]. The positive control (Ct+) was T98G GBM TMZ-S cells that were treated
for 72 hours in the presence of 150 μM TMZ. (C) Numbers of cell division events detected during the 72-hour treatment of TMZ-S and
TMZ-LTT. The relative number of mitosis is the number of cell divisions counted and normalized by the number of cells counted in the
first frame. (D) Illustration of the three genes whose expressions have been the most markedly activated by long-term TMZ treatment in
U373 OR T98 versus U373 and T98G GBM cells.
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the silencing ofAKR1C1 andAKR1C2 because the homology of the two
genes is high, preventing us from obtaining selective AKR1C1 versus
AKR1C2 siRNA.
The data revealed that transient silencing of AKR1C3 in U373
TMZ-LTT GBM cells significantly decreased their global growth rate
(as assessed by the GGR index in Figure 6). Western blot analysis
revealed the efficiency of knockdown using the AKR1C3 siRNA (Fig-
ure 6). Silencing AKR1C3 in U373 and T98G TMZ-LTT GBM
cells did not alter their sensitivity to a variety of cytotoxic drugs (data
not shown). Altogether, these data suggest that TMZ-induced in-
creases in AKR1C3 expression did not modify GBM cell sensitivity
to cytotoxic drugs, whereas U373 GBM cells defended themselves in
Figure 3. Left panels: Determination of GLUT-1, -3, -5, and -10 mRNA levels (by means of an Affymetrix whole genome analysis; see
Materials andMethods) in human T98G and U373 TMZ-S (open bars) and TMZ-LTT (gray bars) GBM cells. The data are illustrated asmedians
andMADs (error bars). Right panels: Determination ofGLUT-1, -3, -5, and -10mRNA levels in a clinical series of 23 normal brain samples (NB)
and 159 gliomas (O-II = oligodendroglioma grade 2 [n=38], O-III = oligodendroglioma grade 3 [n=12], A-II = astrocytoma grade 2 [n=10],
A-III = astrocytoma grade 3 [n = 19], and GBM = GBM grade 4 [n = 77]). Data were extracted from microarray experiments performed at
the Henry Ford Hospital GSE4290), as described in the Materials and Methods section. Data are reported as individual tissue measurements
(1 tissue measurement = 1 black dot) and median values (bars). Statistical comparisons have been performed between each tumor group
and the normal brain tissue (control) group.
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increasing their proliferation rates (Figure 2), a feature that translated
in vivo by an increased biological aggressiveness (Figure 1). AKR1C3
thus seems implicated in this process observed in U373 GBM cells.
In contrast, T98G GBM cells became dependent on TMZ for their
growth as detailed previously (Figure 2).
Discussion
Gliomas account formore than 50%of all primary brain tumors [1–6].
The worst prognosis is associated with gliomas of astrocytic origin,
whereas gliomas with an oligodendroglial origin offer a higher sensitiv-
ity to chemotherapy, especially when oligodendroglioma cells display
1p19q deletions [1,4]. TMZ provides therapeutic benefits and is com-
monly used with radiotherapy in highly malignant astrocytic tumors,
including GBMs [1–7]. However, all GBMs become resistant to TMZ
[43]. Nevertheless, it seems that glioma cell sensitivity to TMZ may
differ in whether they arose from oligodendroglial versus astroglial pro-
genitors. Indeed, we recently reported increased TMZ sensitivity of
Hs683 orthotopic malignant oligodendrogliomas that were previously
treated in vitro with increasing TMZ concentrations before being
xenografted into the brains of immunocompromisedmice [30].Whole
genome and proteomic analysis revealed that this increased TMZ sen-
sitivity could be explained, at least partly, by a TMZ-induced p38-
dependent dormancy state, which in turn resulted in changes in amino
acid metabolism balance, delay in growth, and a decrease in Hs683
oligodendroglioma cell–invasive properties [30].
In the current study, we made use of two GBM cell lines of astrocytic
origin, namely, U373 and T98G [22,23], and observed that TMZ resis-
tance acquired by these two cells lines translated into overexpression of
several glucose transporters (GLUT) and of three members of the aldo-
keto reductase (AKR) family, namely, AKR1C1, AKR1C2, andAKR1C3.
Figure 4. Western blot analysis of GLUT-10 (A) and GLUT-3 (B) expression in T98G and U373 TMZ-S and TMZ-LTT GBM cells. (C) Low-
magnification (×80) immunofluorescence analysis of GLUT-10 in U373 GBM cells with TMZ-LTT (Cb) versus TMZ-S (Ca). The white arrows
point to a very intense GLUT-10–associated spot that is apparent in each U373 GBM cell. High-magnification (×400) of bright-field (Cc)
versus immunofluorescence (Cd) analyses in U373 TMZ-LTT are also provided: the blue DAPI stain reveals the nucleus of a U373 TMZ-LTT
GBM cell, whereas the green stain highlightsGLUT-10 perinuclear localization. (D) Low-magnification (×80) immunofluorescence analysis of
GLUT-3 protein expression in TMZ-LTT (Db) versus TMZ-S (Da) U373 GBM cells. The white arrows point to a very intense GLUT-3–associated
spot that is apparent in each U373 GBM cell.
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As emphasized by Gatenby and Gillies [44], a near-universal prop-
erty of primary and metastatic cancers is up-regulation of glycolysis,
resulting in increased glucose consumption, a feature that was elucidated
in 1956 by Warburg [45]. Persistent metabolism of glucose to lactate
even in aerobic conditions seems to be an adaptation to intermittent
hypoxia [46]. HIF-1α, a hypoxia-activated transcription factor, is impli-
cated in the overexpression of several important enzymes implicated in
the conversion of glucose into lactate [46].
Figure 5. Left panels: Determination of AKR1C1, AKR1C2, and AKR1C3 mRNA levels of expression (by means of an Affymetrix whole genome
analysis;seeMaterials andMethods) inhumanT98GandU373TMZ-S (openbars) andTMZ-LTT (graybars)GBMcells.Dataare illustratedasmedians
andMADs (error bars). Right panels: Determination ofAKR1C1,AKR1C2, andAKR1C3mRNAexpression levels in a clinical series of 23 normal brain
samples (NB)and159gliomas (O-II=oligodendrogliomagrade2 [n=38],O-III=oligodendrogliomagrade3 [n=12],A-II=astrocytomagrade2 [n=
10], A-III = astrocytoma grade 3 [n= 19], and GBM=GBM, grade 4 [n= 77]). Data were extracted frommicroarray experiments performed at the
Henry Ford Hospital as described inMaterials andMethods section. Data are reported as individual tissuemeasurements (1 tissuemeasurement=
1black dot) andmedian values (bars). Statistical comparisons have beenperformedbetween each tumor group and the normal brain tissue (control)
group. Bottom: Western blot analysis of AKR1C2 and AKR1C3 protein expression in T98G and U373 TMZ-S and TMZ-LTT GBM cells.
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Our data reveal that long-term treatment of astroglioma U373 and
T98G cells leads to overexpression of GLUT-1, -3, and -10. Hypoxia
increases the expression of GLUT-1 [47,48], GLUT-3 [48], and
GLUT-10 [47]. Therefore, it seems that astroglioma cells facing ad-
verse TMZ-induced events react by overexpressing GLUT transpor-
ters and subsequently increasing glucose intake to partly counteract
the TMZ-induced antiangiogenic effects [11]. Indeed, glycolytic
breakdown of glucose is preceded by the transport of glucose across
the cell membrane, a rate-limiting process mediated by facilitative
glucose transporter proteins belonging to the facilitative glucose
transporter/solute carrier GLUT/SLC2A family [44,48]. Mutations
in GLUT-10 alter angiogenesis [42]. Overexpression of GLUT-3
mRNA is correlated with tumor grade, and protein expression of this
glucose transporter has been demonstrated in GBM but not in other
grade [49]. Nishioka et al. [50] have suggested that the increased expres-
sion of GLUT-3 may be closely related to the malignant progression of
astrocytomas to GBMs and related to the aberrant neovascularization
that accompanies GBMs. GLUT-3 indeed seems to be a GLUT trans-
porter that correlates directly with glioma aggressiveness [49,51]. Fur-
thermore, our current data clearly show that long-term treatment of
both U373 and T98G GBM cells translates into overexpression of
GLUT-3 (Figures 3 and 4).
Other studies have reported associations between increased GLUT
expression and increased proliferative indices [48,52]. It is well known
that astrocytes play a role in brain metabolism, being a key element in
the capture of energetic compounds from the circulation and deliver-
ing these compounds to active neurons [53]. Glioma cells display higher
proliferation rates than normal astrocytes, and this proliferative dysfunc-
tion is associated with changes in gap junction communication [53]. In-
deed, the inhibition of gap junction communication is associated with
an increase in glucose uptake because of a rapid change in the localiza-
tion of bothGLUT-1 and type 1 hexokinase; this effect persists from the
up-regulation ofGLUT-1 and type 1 hexokinase and to the induction of
GLUT-3 and type 2 hexokinase [53]. In addition, cyclins D1 and D3
have been found to act as sensors of the inhibition of gap junctions and
have been proposed to play the role of mediators in the observed mito-
genic effect [53]. All of these features may partly explain the data we
report here. The data suggest potential relationships between GLUTex-
pression, cell proliferation, and partial acquisition of resistance to TMZ,
at least in U373 GBM cells, which diffusely invade the brain paren-
chyma [54] and display higher biological aggressiveness compared with
T98G GBM cells [22,23].
GLUT-5 is a particular glucose transporter because it displays a
high affinity for fructose and a low affinity for glucose [55]. The data
from the present study show that GLUT-5 is expressed at very low
basal levels in U373 GBM cells but is not expressed in T98G GBM
cells and that long-term TMZ treatment augments its expression in
U373 GBM cells (Figure 3).
AKR1C1, AKR1C2, and AKR1C3 are members of the AKR
superfamily [56]. The AKR1C family of proteins are phase 1 drug-
metabolizing enzymes involved in the maintenance of steroid homeo-
stasis, prostaglandin metabolism, and metabolic activation of polycyclic
aromatic hydrocarbons [56,57]. Increased expression of AKR1C proteins
directly correlates with poor prognosis in breast and prostate cancers [56]
and with chemoresistant features in non–small cell lung [58] and colon
[59] cancer. The data in the current study reveal that the expression of
AKR1C1, AKR1C2, and AKR1C3 was significantly increased in both
U373 and T98GGBMcells (at both the mRNA and protein levels) after
long-term TMZ treatment (Figure 5). Transient silencing of AKR1C3
protein in both U373 TMZ-LTT GBM cells induced a decrease in pro-
liferation rates (Figure 6) but an increase in chemosensitivity of AKR1C3-
deficient U373 and T98G TMZ-LTT cells when compared with naive
(wild-type) U373 and T98G TMZ-LTT cells. Chien et al. [57] estab-
lished mouse NIH3T3 mouse cell lines ectopically and stably expressing
human AKR1C1, AKR1C2, or AKR1C3 and showed that ectopic expres-
sion of human AKR1C1 and AKR1C2, but not AKR1C3, significantly
enhanced foci formation. After subcutaneous injection of these stable
cell lines into nude mice, fibrosarcomas formed from all three cell lines
[57]. However, the number and size of tumors formed by the AKR1C3-
expressing cell line was fewer and smaller than those formed by
AKR1C1- and AKR1C2-expressing cells [57]. Davies et al. [60] identi-
fied AKR1C isoforms as novel targets of jasmonates in cancer cells. Fur-
thermore, these authors provided further evidence of the promise of
these compounds, or derivatives thereof, as adjunctive therapies in the
treatment of cancer.
Increased levels of expression of AKR1C1 parallels increased cell
proliferation activity in human colon cancer cells [59]. It has been
known that AKR1C3 can catalyze the conversion of prostaglandin
D2 to prostaglandin F2α′, which is an activator of cell proliferation
[61]. This reaction inhibits the natural conversion of prostaglandin
D2 to prostaglandin J2, which is known to be a ligand of peroxysome
proliferator-activated receptor gamma (PPARγ) [61]. The activation of
PPARγ by a natural agonist (such prostaglandin J2) usually increases the
expression of GLUT-3, as demonstrated by Garcia-Bueno et al. [62].
Thus, although we observed an overexpression of AKR1C3, we should
Figure 6. Upper panel: GGR computed at 3, 5, 7, and 9 days in
AKR1C3 siRNA-transfected U373 TMZ-LTT GBM cell populations
(see legend to Figure 2A) versus scramble transfected cells. All ex-
periments were performed in triplicate. Bottom panel: Methodo-
logical control (Western blot analysis) of AKR1C3 siRNA versus
scramble siRNA efficiency in U373 TMZ-LTT GBM cells. The West-
ern blot (WB) bands have been digitized, and quantitative data
below the WB bands represent the number of pixels of the band
multiplied by pixel intensity, the final result of which has been nor-
malized to the corresponding tubulin band.
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detect a decrease in cellular GLUT-3 expression. However, the reverse
feature has been observed, and it is already known that HIF-1α acti-
vates transcription ofGLUT-1 and -3 [45]. Thus, altogether, these data
suggest that GLUT-3 overexpression is controlled by HIF-1α rather
than by the PPARγ signaling pathways.
In conclusion, our data show that long-term treatment of human
astroglioma cells with TMZ induces increased expression of facilitative
glucose transporter/solute carrier GLUT/SLC2A family members, pri-
marily GLUT-3, and of the AKR1C family of proteins that are phase 1
drug-metabolizing enzymes involved in the maintenance of steroid
homeostasis, prostaglandin metabolism, and metabolic activation of
polycyclic aromatic hydrocarbons. GLUT-3 has previously been sug-
gested to exert roles in GBM neovascularization processes, whereas
TMZ has been shown to exert antiangiogenic effects in experimental
gliomas. AKR1C1 has previously been shown to be associated with
oncogenic potential and proproliferative effects, as has AKR1C3 in this
latter case. Both AKR1C1 and AKR1C2 proteins are involved in cancer
cell chemoresistance. Selective targeting of GLUT-3 and/or AKR1C
proteins (bymeans of jasmonates, in the case of AKR1C) inGBMcould
delay the acquisition of resistance to TMZ by astroglioma cells when
treated for long periods with this drug.
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